OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Case-Based Insights on Multiple Myeloma

home / insights / case-based-myeloma
Increasingly Improved Outcomes for Multiple Myeloma

EP. 1: Increasingly Improved Outcomes for Multiple Myeloma

December 8th 2017
Multiple Myeloma: Upfront Therapy and Longer Remissions

EP. 2: Multiple Myeloma: Upfront Therapy and Longer Remissions

December 8th 2017
Strategies for Upfront Therapy in Multiple Myeloma

EP. 3: Strategies for Upfront Therapy in Multiple Myeloma

December 8th 2017
Understanding Treatment Planning in Multiple Myeloma

EP. 4: Understanding Treatment Planning in Multiple Myeloma

December 8th 2017
The Current Role of Transplant in Multiple Myeloma

EP. 5: The Current Role of Transplant in Multiple Myeloma

December 8th 2017
Multiple Myeloma: Optimizing Approaches to Transplant

EP. 6: Multiple Myeloma: Optimizing Approaches to Transplant

December 8th 2017
Maintenance Therapy's Value in Multiple Myeloma

EP. 7: Maintenance Therapy's Value in Multiple Myeloma

December 8th 2017
Multiple Myeloma: Understanding and Treating Progression

EP. 8: Multiple Myeloma: Understanding and Treating Progression

December 8th 2017
Multiple Myeloma: Using Novel Therapies at Relapse

EP. 9: Multiple Myeloma: Using Novel Therapies at Relapse

December 8th 2017
Multiple Myeloma: Considerations in Treating Relapse

EP. 10: Multiple Myeloma: Considerations in Treating Relapse

December 8th 2017
Multiple Myeloma: Second Relapse and Beyond

EP. 11: Multiple Myeloma: Second Relapse and Beyond

December 8th 2017
Case Study 1: A Diagnosis of Stage II Multiple Myeloma

EP. 12: Case Study 1: A Diagnosis of Stage II Multiple Myeloma

December 8th 2017
Case Study 1: Follow-Up Strategies for Multiple Myeloma

EP. 13: Case Study 1: Follow-Up Strategies for Multiple Myeloma

December 8th 2017
Case Study 1: Treating MM After RVd and Transplant

EP. 14: Case Study 1: Treating MM After RVd and Transplant

December 8th 2017
Case Study 1: The Value of KRd in Multiple Myeloma

EP. 15: Case Study 1: The Value of KRd in Multiple Myeloma

December 8th 2017
Case Study 2: An Elderly Patient With Multiple Myeloma

EP. 16: Case Study 2: An Elderly Patient With Multiple Myeloma

December 8th 2017
Case Study 2: Options for Biochemically Relapsed MM

EP. 17: Case Study 2: Options for Biochemically Relapsed MM

December 8th 2017

Latest Conference Coverage

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase

ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact